Winship Cancer Insititute of Emory University
Welcome,         Profile    Billing    Logout  
 5 Trials 
7 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
NGuyen, Kim
NCT05894707: Evaluate the Safety and Tolerability of SCT650C in Healthy Volunteers

Not yet recruiting
1
32
RoW
SCT650C, Recombinant anti-IL-17A antibody
Sinocelltech Ltd.
Autoimmune Disease
11/23
03/24
RECCLAIM-II, NCT03804060: REperfusion With Cooling in CerebraL Acute IscheMia II

Completed
N/A
90
US
Thermogard XP3, Recanalization only
ZOLL Circulation, Inc., USA
Ischemic Stroke
05/24
05/24
Akce, Mehmet
NCT05103904: Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant

Recruiting
2
19
US
Laboratory Biomarker Analysis, Lenvatinib, E7080, ER-203492-00, Multi-Kinase Inhibitor E7080
Emory University, National Cancer Institute (NCI), Eisai Co., Ltd.
Recurrent Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC V8, Stage IIIA Hepatocellular Carcinoma AJCC V8, Stage IIIB Hepatocellular Carcinoma AJCC V8, Stage IV Hepatocellular Carcinoma AJCC V8, Stage IVA Hepatocellular Carcinoma AJCC V8, Stage IVB Hepatocellular Carcinoma AJCC V8, Unresectable Hepatocellular Carcinoma
11/25
11/26
TAPUR, NCT02693535: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Recruiting
2
3791
US
Palbociclib, Ibrance, Sunitinib, Sutent, Temsirolimus, Torisel, Trastuzumab and Pertuzumab, Herceptin and Perjeta, Vemurafenib and Cobimetinib, Zelboraf and Cotellic, Regorafenib, Stivarga, Olaparib, Lynparza, Pembrolizumab, Keytruda, Nivolumab and Ipilimumab, Opdivo and Yervoy, Abemaciclib, Verzenio, Talazoparib, Talzenna, Atezolizumab and PHESGO, Tecentriq and PHESGO, Atezolizumab and Talazoparib, Tecentriq and Talzenna, Entrectinib, Rozlytrek, Larotrectinib, Vitrakvi, Tucatinib plus Trastuzumab Subcutaneous (SC), Tukysa and Herceptin Hylecta, Futibatinib, Lytgobi
American Society of Clinical Oncology, AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Inc., Merck Sharp & Dohme LLC, Pfizer, Boehringer Ingelheim, Seagen Inc., Taiho Oncology, Inc.
Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
06/26
06/27
NCT06728410: A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement

Not yet recruiting
2
38
US
Pemigatinib, PEMAZYRE, Durvalumab, Imfinzi
Mehmet Akce, AstraZeneca, Incyte Corporation, University of Alabama at Birmingham
Intrahepatic Cholangiocarcinoma, FGFR2 Gene Rearrangement, FGFR2 Gene Mutation
07/26
07/27
NCT04650451: Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors

Suspended
1/2
220
US
chimeric antigen receptor (CAR) T cell therapy, CAR-T, BPX-603, autologous CAR-T
Bellicum Pharmaceuticals
HER-2 Gene Amplification, HER2-positive Gastric Cancer, HER2-positive Breast Cancer, HER-2 Protein Overexpression, Solid Tumor, Adult
12/25
01/27
NCT06182072: ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)

Recruiting
1
28
US
ProAgio Dose Levels (DL) 1,2,3,4, ACT50, Gemcitabine, nab paclitaxel, (G-nP)
ProDa BioTech, LLC, University of Alabama at Birmingham, Georgia State University
Pancreatic Ductal Carcinoma
07/25
10/25

Download Options